Hoth Therapeutics, Inc. Annual Report: A Simple Breakdown

I’ve put together this guide to help you understand how Hoth Therapeutics performed this year. My goal is to turn complex financial filings into plain English so you can decide if this company fits your investment goals.

1. What does this company do?

Hoth Therapeutics is a "lab-in-a-box" drug developer. They don’t sell products in pharmacies. Instead, they license ideas from universities and guide them through clinical trials. Their current pipeline includes:

• HT-001: A topical treatment for skin rashes caused by cancer therapies.
• HT-KIT: A treatment for mast-cell-related cancers, currently in early development.
• HT-ALZ: A potential treatment for Alzheimer’s disease.
• BioLexa: A platform to treat eczema and prevent skin infections.
• HT-VA: A new approach to weight management and obesity.

2. Financial performance: The "Spending" Phase

Hoth is in a "spending" phase. They have no product sales, so they lose money every year. In 2023, the company lost about $10.6 million, compared to $11.8 million in 2022.

Most of their money goes toward research and administrative costs. Since they don’t earn revenue, they fund their operations by selling more shares of stock. In 2023, they raised about $10.3 million this way.

3. Financial health: A serious warning

The company’s auditors are concerned about Hoth’s ability to stay in business. As of late 2023, they had $7.1 million in cash. At their current spending rate, this won't cover their costs for the next year, meaning they will need to raise more money soon.

The company often sells new shares to raise cash. This creates more shares, which reduces your ownership percentage in the company. They also face pressure to keep their stock price above $1.00 to stay on the Nasdaq exchange. If they are kicked off the exchange, it will be much harder for them to raise money or for you to trade the stock.

4. Major risks

This is a high-risk investment. The company depends entirely on outside funding and successful drug trials:

• Funding & Dilution: Hoth has lost $64.8 million since it started. To keep going, they must raise more money, which will continue to reduce your ownership stake.
• Clinical Trials: Developing a drug takes years and hundreds of millions of dollars. If a drug fails at any stage of testing, it likely becomes worthless.
• Third-Party Reliance: Hoth hires outside labs to do their work. If these partners fail or fall behind, Hoth has no internal team to fix the problem.
• Legal & Regulatory: Hoth relies on licenses from universities. If they miss payment deadlines or fail to develop the drugs on time, they could lose the rights to their core products.

5. Future outlook

Hoth is focusing on HT-001 and has received approval to expand trials into Europe. They are also moving into the weight-loss market to attract more interest. However, their survival depends on raising cash in a tough market and passing strict FDA tests.

Think of Hoth as a high-risk, speculative bet. Their goal is to reach a major milestone—like positive test results or a partnership with a big drug company—before they run out of cash.

Final Thought for Investors: Before investing, ask yourself if you are comfortable with the "all-or-nothing" nature of biotech startups. Because Hoth relies on selling shares to fund its operations, your investment could be diluted over time. This company is best suited for those who understand the risks of early-stage drug development and are looking for a long-term, speculative opportunity rather than immediate stability.